Q-omics provides the consensus-scored MYO1D profile across patient tissues and cancer cell-line models. MYO1D expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, MYO1D is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, MYO1D protein abundance shows 27,808 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight BLCA, KIRC, and LUAD as cancer lineages where MYO1D shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYO1D — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYO1D survival associations across molecular data types. MYO1D RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYO1D RNA expression–survival associations across cancer types. High MYO1D expression shows unfavorable associations in BLCA, SKCM, UCEC and LUAD, but favorable associations in KIRC and READ. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for MYO1D RNA expression.
This table summarizes MYO1D tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MYO1D. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYO1D shows lower tumor expression in KIRC, KICH and READ and higher tumor expression in HNSC, BRCA and BLCA. The KIRC box plot shows higher MYO1D RNA expression in normal versus tumor tissue (log2 FC = −0.706, t-test p < 0.001).
This table shows molecular features associated with MYO1D in patient tissues and cancer cell lines. In patient samples, MYO1D shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, MYO1D RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and LUNG_SCLC.
